Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jul 11;104(28):e43245.
doi: 10.1097/MD.0000000000043245.

Risk factors of urinary tract infections with sodium-glucose cotransporter-2 inhibitors in heart failure

Affiliations
Observational Study

Risk factors of urinary tract infections with sodium-glucose cotransporter-2 inhibitors in heart failure

Yuan-Yuan Zhang et al. Medicine (Baltimore). .

Abstract

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, while providing cardiorenal benefits in heart failure, have been associated with an elevated risk of urinary tract infections (UTIs). This study aimed to identify independent risk factors for UTIs in HF patients receiving SGLT-2 inhibitor therapy. In this multicenter retrospective cohort study, 110 heart failure patients treated with SGLT-2 inhibitors were included, among whom 41 developed UTIs. Comparative analyses between UTI and non-UTI groups were performed for demographic, clinical, and laboratory variables. Statistically significant factors (P < .05) in univariate logistic regression were subsequently entered into a multivariate model using backward stepwise elimination to adjust for potential confounders. Multivariate analysis identified 3 independent predictors of UTIs: female (odds ratio [OR] = 8.87, 95% confidence interval [CI]: 2.24-33.81; P = .002), elevated urinary ketones (OR = 10.59, 95% CI: 1.49, 75.44; P = .019), and prolonged bedridden status (OR = 46.96, 95% CI: 4.03, 547.35; P = .002). Notably, glycosuria severity did not significantly correlate with UTI risk in adjusted models. The identified risk factors - female, ketonuria, and immobility - challenge the conventional hypothesis linking SGLT-2 inhibitor-associated glycosuria to UTIs. Instead, these findings emphasize patient-specific vulnerabilities, particularly immune-metabolic dysregulation and functional decline, as primary drivers of infection risk. Clinicians should prioritize individualized monitoring strategies in high-risk subgroups to optimize therapeutic safety.

Keywords: heart failure; sodium-glucose cotransporter-2 inhibitors; urinary tract infections.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Risk factors determined by logistic regression analysis. Multivariate logistic regression determined 3 independent risk factors, including gender (male) with odds of 0.115 (P = .002), increased urinary ketone with odds of 10.585 (P = .019), and long-term bedridden with odds of 46.961 (P = .002).

References

    1. Philip H. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia. 2019;62:357–69. - PubMed
    1. Dario G, Miriam L, Lorenzo S, Giuseppe B, Maria Ida M, Katherine E. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021;20:236. - PMC - PubMed
    1. Administration, U.S.F.D. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2022. https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-label.... Accessed March 15, 2022.
    1. Soleimani H, Saeedian B, Pasebani Y, et al. Safety of sodium-glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta-analysis. ESC Heart Fail. 2024;11:637–48. - PMC - PubMed
    1. Lunati M, Cimino V, Gandolfi A, et al. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol Res. 2022;183:106396. - PubMed

Publication types

Substances